Potent, transient inhibition of BCR-ABL with dasatinib 100...

Haematologica 2010 / 02 Vol. 95; Iss. 2

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib

Shah, N. P., Kim, D.-W., Kantarjian, H., Rousselot, P., Llacer, P. E. D., Enrico, A., Vela-Ojeda, J., Silver, R. T., Khoury, H. J., Muller, M. C., Lambert, A., Matloub, Y., Hochhaus, A.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
95
Language:
english
Journal:
Haematologica
DOI:
10.3324/haematol.2009.011452
Date:
February, 2010
File:
PDF, 279 KB
english, 2010
Conversion to is in progress
Conversion to is failed